NEOG vs TRIB
Neogen Corporation and Trinity Biotech PLC, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | NEOG | TRIB |
|---|---|---|
| Revenue | $894.7M | $61.6M |
| Net income | $-1.1B | $-31.8M |
| Gross margin | 47.1% | 34.8% |
| Net margin | −122.1% | −51.6% |
| Return on equity | −41.9% | — |
| Diluted EPS | −$5.03 | — |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $-46.4M | $-4.6M |
| Equity | $2.1B | — |
| Net debt / equity | 0.37× | — |
| Current ratio | 3.32× | 1.28× |
| Revenue CAGR 5y | 16.4% | −7.4% |
| Profit CAGR 5y | — | — |
NEOG bills 14.5× the revenue of TRIB, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | NEOG | TRIB |
|---|---|---|
| FY2024 | $894.7M | $61.6M |
| FY2023 | $924.2M | $56.8M |
| FY2022 | $822.4M | $62.5M |
| FY2021 | $527.2M | $81.1M |
| FY2020 | $468.5M | $102.0M |
| FY2019 | $418.2M | $90.4M |
| FY2018 | $414.2M | $97.0M |
| FY2017 | $397.9M | $99.1M |
| FY2016 | $358.3M | $99.6M |
| FY2015 | $321.3M | $100.2M |
Net income by year
Bottom line
| Fiscal year | NEOG | TRIB |
|---|---|---|
| FY2024 | $-1.1B | $-31.8M |
| FY2023 | $-9.4M | $-24.0M |
| FY2022 | $-22.9M | $-41.0M |
| FY2021 | $48.3M | $875,000 |
| FY2020 | $60.9M | $-6.4M |
| FY2019 | $59.5M | $-28.9M |
| FY2018 | $60.2M | $-22.1M |
| FY2017 | $63.1M | $-40.3M |
| FY2016 | $43.8M | $-100.6M |
| FY2015 | $36.6M | $21.8M |
Advertisement
AdSense · Rectangle 336×280
More in this industry